Mostly Microbes and Infection - by David Ojcius

GORG‑Dark, a dataset of 9,698 single‑cell genomes from deep‑ocean prokaryoplankton, reveals extensive vertical stratification, unexpected particle‑attached Pelagibacterales, and high Patescibacteria and Nanoarchaeota abundance in marginal seas. Coding analyses uncover chemolithoautotrophy, novel proteorhodopsins, and secondary metabolisms across aphotic lineages.

Incretin therapies now improve multiple obesity‑related diseases, with expanding organ‑specific indications. This review explains their mechanisms, evaluates evidence across conditions, and provides a practical framework for using incretin agents beyond endocrinology—covering drug selection, sequencing, monitoring, safety, long‑term management, and access‑limited prescribing.

Predicted bacteriocin genes reveal potential but not function. This review defines four forms of bacteriocin silence—transcriptional, conditional, phenotypic, and ecological—and outlines a function‑first roadmap using condition‑resolved omics, cue‑dissection, structured assays, and defined consortia to link gene catalogs to real ecological impact.

Researchers identify PfSR1‑MT as a melatonin‑responsive GPCR‑like receptor in Plasmodium falciparum . PfSR1‑MT binds melatonin with high affinity, triggers ECD movement and Ca²⁺ signaling, and is selectively activated by ARL34, which inhibits parasite growth and gametocyte development, highlighting a promising antimalarial target.

SCFA‑producing gut bacteria are depleted in Alzheimer’s disease, weakening microbiota‑gut‑brain axis control of neuroinflammation. SCFAs shape microglial and astrocytic states, suppress NLRP3 activation, and influence amyloid, tau, and synaptic integrity. The review evaluates dietary, probiotic, postbiotic, and FMT strategies and outlines biomarker‑guided, personalized therapeutic approaches.

GLP‑1 analogs rely on structural features that enhance stability, receptor affinity, and half‑life. N‑terminal protection, C‑terminal and backbone stabilization, and lipidation drive potency and duration, while structural variation shapes signaling bias. Multi‑receptor agonists and computational design now guide next‑generation incretin therapies.